Patents by Inventor Jerry Evarts

Jerry Evarts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10442805
    Abstract: Polymorphs of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed. Solvent forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are also disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: October 15, 2019
    Assignee: Gilead Calistoga LLC
    Inventors: Suzanne Buttar, Ernest Carra, Tracy Ehiwe, Duong Tran, Fang Wang, Christopher Worrall, Jerry Evarts
  • Patent number: 10308639
    Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein X, Y, Z, n, m?, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: June 4, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Jerry Evarts, Joshua Kaplan, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Jennifer A. Treiberg, Suet Chung Yeung
  • Patent number: 10221197
    Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A?, W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: March 5, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer A. Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
  • Patent number: 10167291
    Abstract: In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: January 1, 2019
    Assignee: Acerta Pharma B.V.
    Inventors: Fritz Blatter, Tim Ingallinera, Tjeerd Barf, Edwin Aret, Cecile Krejsa, Jerry Evarts
  • Patent number: 10059677
    Abstract: A process for the synthesis of benzoxazinone containing compounds which may be useful precursors for synthesizing compounds for the treatment of cancer, is hereby disclosed.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: August 28, 2018
    Assignee: Gilead Calistoga LLC
    Inventors: Stacy Bremner, Jerry Evarts, Keiko Sujino, Duong Tran, Dragos Vizitiu
  • Patent number: 10047060
    Abstract: A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 14, 2018
    Assignee: Gilead Calistoga LLC
    Inventors: Stacy Bremner, Jerry Evarts, Keiko Sujino, Duong Tran, Dragos Vizitiu
  • Publication number: 20180208596
    Abstract: In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents.
    Type: Application
    Filed: September 18, 2017
    Publication date: July 26, 2018
    Inventors: Fritz Blatter, Tim Ingallinera, Tjeerd Barf, Edwin Aret, Cecile Krejsa, Jerry Evarts
  • Publication number: 20180162826
    Abstract: A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.
    Type: Application
    Filed: November 17, 2017
    Publication date: June 14, 2018
    Inventors: Stacy BREMNER, Jerry EVARTS, Keiko SUJINO, Duong TRAN, Dragos VIZITIU
  • Publication number: 20180065953
    Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.
    Type: Application
    Filed: August 17, 2017
    Publication date: March 8, 2018
    Inventors: Jerry Evarts, Joshua A. Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Lafe J. Purvis, II, Kirk L. Stevens, Jennifer Anne Treiberg
  • Publication number: 20180009811
    Abstract: Polymorphs of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed. Solvent forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are also disclosed.
    Type: Application
    Filed: June 16, 2017
    Publication date: January 11, 2018
    Inventors: Suzanne BUTTAR, Ernest CARRA, Tracy EHIWE, Duong TRAN, Fang WANG, Christopher WORRALL, Jerry Evarts
  • Patent number: 9796721
    Abstract: In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: October 24, 2017
    Assignee: Acerta Pharma B.V.
    Inventors: Fritz Blatter, Tim Ingallinera, Tjeerd Barf, Edwin Aret, Cecile Krejsa, Jerry Evarts
  • Patent number: 9765060
    Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: September 19, 2017
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Lafe J. Purvis, II, Kirk L. Stevens, Jennifer A. Treiberg
  • Patent number: 9708327
    Abstract: Polymorphs of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed. Solvent forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are also disclosed.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: July 18, 2017
    Assignee: GILEAD CALISTOGA LLC
    Inventors: Suzanne Buttar, Ernest Carra, Tracy Ehiwe, Duong Tran, Fang Wang, Christopher Worrall, Jerry Evarts
  • Publication number: 20170107187
    Abstract: A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.
    Type: Application
    Filed: December 28, 2016
    Publication date: April 20, 2017
    Inventors: Stacy BREMNER, Jerry EVARTS, Keiko SUJINO, Duong TRAN, Dragos VIZITIU
  • Patent number: 9567337
    Abstract: A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: February 14, 2017
    Inventors: Stacy Bremner, Jerry Evarts, Keiko Sujino, Duong Tran, Dragos Vizitiu
  • Publication number: 20170029428
    Abstract: In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents.
    Type: Application
    Filed: July 1, 2016
    Publication date: February 2, 2017
    Inventors: Fritz Blatter, Tim Ingallinera, Tjeerd Barf, Edwin Aret, Cecile Krejsa, Jerry Evarts
  • Publication number: 20160376274
    Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 29, 2016
    Inventors: Ernest Carra, Michael Gerber, Bing Shi, Keiko Sujino, Duong Tran, Fang Wang, Jerry Evarts
  • Patent number: 9266878
    Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: February 23, 2016
    Assignee: Gilead Calistoga LLC
    Inventors: Jerry Evarts, Leena Patel, Jennifer A. Treiberg, Stephane Perreault, Arthur Yeung, Lafe J. Purvis, II, Musong Kim
  • Publication number: 20160039793
    Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts or isomers thereof, in which n, m, R1, R2, R4, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts or isomers thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.
    Type: Application
    Filed: October 21, 2015
    Publication date: February 11, 2016
    Inventors: Jerry Evarts, Joshua Kaplan, Musong Kim, Leena Patel, Stephane Perreault, Gary Phillips, Jennifer A. Treiberg, Joshua Van Veldhuizen
  • Publication number: 20160024054
    Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PBK) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.
    Type: Application
    Filed: June 23, 2015
    Publication date: January 28, 2016
    Inventors: Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Lafe J. Purvis, II, Kirk L. Stevens, Jennifer A. Treiberg